Skip to Content
Merck
All Photos(1)

Documents

T-039

Supelco

Topiramate solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C12H21NO8S
CAS Number:
97240-79-4
Molecular Weight:
339.36
EC Number:
200-659-6
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1

InChI

1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1

InChI key

KJADKKWYZYXHBB-XBWDGYHZSA-N

Gene Information

human ... CA2(760) , CA4(762) , GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879) , GRIA1(2890) , GRIA2(2891) , GRIA3(2892) , GRIA4(2893) , GRIK1(2897) , GRIK2(2898) , GRIK3(2899) , GRIK4(2900) , GRIK5(2901) , SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

General description

A certified solution standard suitable for use in LC/MS or GC/MS applications for pharmaceutical research, clinical toxicology, or forensic testing.  Topiramate, sold under trade name Topamax®, is an antiepileptic drug used for treatment of seizures. Topiramate in combination with the stimulant phentermine constitute the active compounds in the new weight lose drug Qsymia®.

Application


  • Topiramate research solution: Research focuses on the development of intravenous formulations of topiramate for rapid intervention in seizure emergencies, highlighting its potential in emergency medicine and critical care (Epilepsy Behav, 2023; doi: 10.1016/j.yebeh.2023.109158).

  • Topiramate liquid formulation: Innovations in drug delivery include the use of topiramate-chitosan nanoparticles, which offer enhanced drug stability and targeted delivery, particularly in addiction treatment settings (Neurochem Int, 2021; doi: 10.1016/j.neuint.2021.105157).

  • Anticonvulsant biochemical reagent: Topiramate′s role as an anticonvulsant is further explored in studies focusing on its pharmacokinetic properties and interaction with other medications, emphasizing its importance in personalized medicine (Ther Drug Monit, 2019; doi: 10.1097/FTD.0000000000000600).

  • Topiramate in vitro study: The compound is utilized in in vitro setups to investigate its effects on neuronal excitability, providing insights into its mechanism of action and potential therapeutic applications (Epilepsia, 2019; doi: 10.1111/epi.16073).

  • Topiramate pharmacological research: Studies include the development of advanced analytical methods for the quantification of topiramate in biological samples, supporting its clinical monitoring and therapeutic drug management (J Pharm Biomed Anal, 2015; doi: 10.1016/j.jpba.2015.01.035).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Qsymia is a registered trademark of Vivus, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Topamax is a registered trademark of Johnson & Johnson

related product

Product No.
Description
Pricing

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J M Riffitts et al.
Journal of pharmaceutical and biomedical analysis, 19(3-4), 363-371 (2000-03-07)
An accurate and robust method involving liquid liquid extraction and capillary gas chromatographic (GC) assay with nitrogen phosphorus detection (NPD) was developed and validated for the quantitative determination of topiramate [2,3:4,5-bis-O-(-1-methylethylidene)-beta-D-fructopyranose sulfamate], Topamax, an anticonvulsant drug, in human plasma, urine
Philip J Wiffen et al.
The Cochrane database of systematic reviews, 8(8), CD008314-CD008314 (2013-09-03)
Topiramate is an antiepileptic drug with multiple possible mechanisms of action. Antiepileptic drugs are widely used to treat chronic neuropathic pain (pain due to nerve damage) and fibromyalgia, and many guidelines recommend them. To assess the analgesic efficacy and associated
Henry R Kranzler et al.
The American journal of psychiatry, 171(4), 445-452 (2014-02-15)
Topiramate has been shown to reduce drinking and heavy drinking in individuals with alcohol dependence whose goal was to stop drinking. The authors evaluated the efficacy and tolerability of topiramate in heavy drinkers whose treatment goal was to reduce drinking
Mattias Linde et al.
The Cochrane database of systematic reviews, 6(6), CD010610-CD010610 (2013-06-26)
Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an
Steve S Chung et al.
Epilepsia, 55(7), 1077-1087 (2014-06-07)
To evaluate the efficacy and safety of USL255, Qudexy(™) XR (topiramate) extended-release capsules, as an adjunctive treatment for refractory partial-onset seizures (POS) in adults taking one to three concomitant antiepileptic drugs. In this global phase III study (PREVAIL; NCT01142193), 249
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service